BioPalette Co., Ltd.

The restructuring of a licensing deal with Bio Palette comes as Beam Therapeutics prepares to file for FDA approval of its base edited autologous cell therapy ristoglogene autogetemcel in sickle cell disease.\n The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology. Having prepared for that outcome, Beam has retained access to the technology under a revised license agreement. Bio Palette licensed the technology from Kobe University to develop engineered bacteria optimized to modify and control the microbiome. Focused on the microbiome, the Japanese biotech out-licensed the right to use the technology in all other ways of treating human disease. Beam paid Bio Palette $500,000 upfront for the license in 2019 and made a $2 million milestone payment the following year. Having secured access to Beam technologies as part of the deal, Bio Palette advanced a pipeline of drug candidates toward the clinic in areas including inflammatory bowel disease and immuno-oncology. Those efforts are now coming to an end. Amid a challenging period for the microbiome field, Beam said Bio Palette is planning to wind down. The partners have mutually terminated their licensing agreement as part of Bio Palette’s dissolution process. The shuttering of Bio Palette threatened Beam’s access to the technology. However, Beam insulated itself from the risk last month by inking a standby licensing agreement with Kobe University and Bio Palette. The agreement was designed to kick in if the original license agreement between Kobe University and Bio Palette ended. With Bio Palette’s dissolution triggering the termination of the original agreement, the standby licensing pact has come into effect. The new agreement gives Beam a direct, exclusive license to the technology from Kobe University. Beam could pay Kobe University royalties, which were previously agreed upon with Bio Palette.The restructuring of the licensing deal comes as Beam prepares to file for FDA approval of its base edited autologous cell therapy ristoglogene autogetemcel in sickle cell disease. Beam recently said it could seek approval as early as the end of this year. 

DUBLIN, Aug. 19, 2022 /PRNewswire/ -- The "Global Microbiome Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering. The Global Microbiome Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Microbiome dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 250 Microbiome deal records and contract documents where available The leading antibody deals by value since 2010 Most active Microbiome dealmakers since 2010 The leading Microbiome partnering resources The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of Microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading Microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active Microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in Microbiome dealmaking with a brief summary followed by a comprehensive listing of Microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by Microbiome partnering company A-Z, deal type definitions and Microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Microbiome partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Microbiome technologies and products. Companies Mentioned 4D Pharma 9 Meters Biopharma Aarhus University Abbott Laboratories Abbvie ADL Bionatur Solutions ADM AIDS Clinical Trials Group Alimentary Health Allergan ALS Association Amag Pharmaceuticals American Type Culture Collection (ATCC) Ancilia Biosciences AnimalBiome AntibioTx Arc Bio Archer Daniels Midland Company Arena Pharmaceuticals Argonne National Laboratory Ariana Pharma Arranta Bio Artizan Biosciences Assembly Biosciences AstraZeneca Aurealis Therapeutics Azitra BASF Bayer Bayer CropScience Bayer Healthcare Baylor College of Medicine Baylor Miraca Genetics Laboratories Beam Therapeutics Bertin Pharma Bill and Melinda Gates Foundation Bio-Me Bio-Rad Laboratories BIOASTER Biocodex Microbiota Foundation Biocogent Biocore Biofortis Biohaven Pharmaceuticals BiomeBank Biomecite Diagnostics Biomedical Advanced Research and Development Authority Biomica Biomillenia Biomodels BiomX BionX Medical Technologies Bio Palette Biosortia Pharmaceuticals Bloom Science Boehringer Ingelheim Boston University School of Medicine Brigham and Women's Hospital Bristol-Myers Squibb Brown University Cancer Research UK CARB-X Carbiotix Cargill Cedars-Sinai Medical Center Centers for Disease Control and Prevention Centre Leon Berard Centre National de la Recherche Scientifique Centro Sperimentale del Latte Children's Hospital Boston Circuit Clinical Clalit Health Services and many, many more! For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday. Nearly seven months after it secured $135 million in a Series B financing round, gene-editing company Beam Therapeutics is eying a listing on the Nasdaq and an initial public offering (IPO) of $100 million. Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday. The company plans to use the ticker symbol “BEAM.” Proceeds from the IPO are expected to be used to support the continued research and development of its base-editing programs, including preclinical studies and IND-enabling studies for its three delivery modalities. Beam launched two years ago. Its programs are currently in preclinical stage of development. Beam’s base-editing platforms were developed in the laboratory of David Liu and its RNA base editor platform was developed by Feng Zhang at the Broad Institute of MIT and Harvard. Beam’s technology is seen as a more precise form of CRISPR gene editing techniques. The promise of the company’s base-editing platform is the potential repair of disease-causing point mutations – changes in a single base. Current CRISP editing, such as with Cas9, cuts out larger chunks of DNA. Beam’s base editing technology is comprised of two key enzymes which zero in on a specific site in the genome and an editing enzyme that changes the base. The base editing technology allows for the rewriting of a mutation in the DNA, which is made up of nucleobases, or “bases,” each represented by a single letter, A, G, T and C. These letters are subsequently encoded in RNA messages for expression by the cell. Base editors are capable of precisely targeting and directly editing just one base out of billions within the genome, without cutting the DNA or RNA. For example, it can change a base from an “A” to a “T.” “If existing gene-editing approaches are ‘scissors’ for the genome, our base editors are ‘pencils,’ erasing and rewriting one letter in the gene,” Beam said in the prospectus it filed with the SEC. As Beam explains, its base-editing platform offers a number of advantages over existing platforms like CRISPR-Cas9. Among the advantages are more precise and predictable editing designed to make only one type of base edit at the desired target location. Earlier this year, Beam presented data at the American Society of Gene and Cell Therapy annual meeting that showed its base editor BE4 demonstrated high-efficiency multiplex base editing of three cell surface targets in primary human T cells, TRAC, B2M, and PD-1. BE4 knocked out expression of each gene in 95%, 95% and 88% of cells, respectively, in a single electroporation, the company said. Each of the genes was silenced by a single targeted base change without the creation of double-strand breaks. That precision showed that the editing of each of the genes may be useful in the creation of CAR-T cell therapies with improved therapeutic properties, Beam said at the time. Following that announcement, Beam and Japan-based Bio Palette forged a cross-licensing agreement around each companies’ base editing intellectual property. Bio Palette is developing new genome editing technologies for use in various fields, including agriculture and the microbiome. hbspt.forms.create({ portalId: "4413123", formId: "c4dda430-e2b0-4083-86f3-ccce0c1d4479" });